221 related articles for article (PubMed ID: 25052849)
1. AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.
Perez SA; Anastasopoulou EA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2014 Nov; 63(11):1141-50. PubMed ID: 25052849
[TBL] [Abstract][Full Text] [Related]
2. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
3. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Anastasopoulou EA; Voutsas IF; Keramitsoglou T; Gouttefangeas C; Kalbacher H; Thanos A; Papamichail M; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2015 Sep; 64(9):1123-36. PubMed ID: 26026288
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
5. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
[TBL] [Abstract][Full Text] [Related]
6. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
7. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
Gates JD; Clifton GT; Benavides LC; Sears AK; Carmichael MG; Hueman MT; Holmes JP; Jama YH; Mursal M; Zacharia A; Ciano K; Khoo S; Stojadinovic A; Ponniah S; Peoples GE
Vaccine; 2010 Nov; 28(47):7476-82. PubMed ID: 20858449
[TBL] [Abstract][Full Text] [Related]
8. Immunologic biomarkers in prostate cancer: the AE37 paradigm.
Baxevanis CN; Papamichail M; Perez SA
Hum Vaccin Immunother; 2014; 10(5):1244-7. PubMed ID: 24552987
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
10. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
[TBL] [Abstract][Full Text] [Related]
11. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
McCarthy PM; Clifton GT; Vreeland TJ; Adams AM; O'Shea AE; Peoples GE
Expert Opin Investig Drugs; 2021 Jan; 30(1):5-11. PubMed ID: 33191799
[TBL] [Abstract][Full Text] [Related]
12. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA; Ardavanis A; Symanowski J; Murray JL; Shumway NM; Litton JK; Hale DF; Perez SA; Anastasopoulou EA; Pistamaltzian NF; Ponniah S; Baxevanis CN; von Hofe E; Papamichail M; Peoples GE
Ann Oncol; 2016 Jul; 27(7):1241-8. PubMed ID: 27029708
[TBL] [Abstract][Full Text] [Related]
13. AE37: a novel T-cell-eliciting vaccine for breast cancer.
Sears AK; Perez SA; Clifton GT; Benavides LC; Gates JD; Clive KS; Holmes JP; Shumway NM; Van Echo DC; Carmichael MG; Ponniah S; Baxevanis CN; Mittendorf EA; Papamichail M; Peoples GE
Expert Opin Biol Ther; 2011 Nov; 11(11):1543-50. PubMed ID: 21895539
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
[TBL] [Abstract][Full Text] [Related]
15. MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.
Anastasopoulou EA; Voutsas IF; Papamichail M; Baxevanis CN; Perez SA
Oncoimmunology; 2016 Jul; 5(7):e1178439. PubMed ID: 27622033
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB
J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.
Johnson LE; Olson BM; McNeel DG
J Immunother Cancer; 2017 Jul; 5(1):56. PubMed ID: 28716080
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
Mittendorf EA; Holmes JP; Murray JL; von Hofe E; Peoples GE
Expert Opin Biol Ther; 2009 Jan; 9(1):71-8. PubMed ID: 19063694
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
[TBL] [Abstract][Full Text] [Related]
20. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
